Isis Drops Genital Wart Treatment
Antisense specialist Isis Pharmaceuticals has decided to withdraw its human papilloma virus inhibitor ISIS 2105 from development, after lackluster results were seen in a Phase II trial of the drug as a surgical adjuvant for patients with genital warts.
The study indicated a trend towards fewer recurrences of genital warts when multiple doses of ISIS 2105 were administered along with cryosurgery, but this was not deemed compelling enough to continue the program. Going on would require the development of a sustained-release formulation, and given that new market research data is downplaying the market potential of such a drug, this was not considered a wise investment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze